Search

Your search keyword '"Guillén N"' showing total 209 results
Start Over Author "Guillén N"
209 results on '"Guillén N"'

2. Corioamnionitis histológica y neurodesarrollo en niños prematuros menores de 34 semanas, Lima-Perú

Author

Vila, J., Guillen Pinto, Daniel, Bellomo, Sicilia, Guillén, N., Vila, J., Guillen Pinto, Daniel, Bellomo, Sicilia, and Guillén, N.

Abstract

The objective of this study was to determine the effects of histologically diagnosed chorioamnionitis on neurodevelopment of premature babies born with less than 34-week gestational age who were assessed at two-year corrected age. A secondary case-control study was carried out. Clinical data, placental histological findings, and development indexes assessed using the Bayley III scale were analyzed in 38 exposed children and 53 non-exposed children. Genitourinary infections in mothers and early sepsis were more frequent in the exposed group (p<0.005). Cognitive development, motor development and language were normal in both groups. Those children exposed to the chorionitis subtype had lower scores in the aforementioned variables. Histologically diagnosed chorioamnionitis did not show any influence on neurodevelopment in premature babies born with less than 34-week gestational age when they were assessed at two years. Longitudinal and multicenter studies are advised in order to define the long-term effects., Para determinar los efectos de la corioamnionitis histológica en el neurodesarrollo de los prematuros menores de 34 semanas evaluados a los 2 años de edad corregida se realizó un estudio secundario de casos y controles. Fueron analizados los datos clínicos, hallazgos histológicos de la placenta e índices del desarrollo medidos por la Escala Bayley III de 38 niños expuestos y 53 niños no expuestos. Las infecciones genitourinarias de la madre y la sepsis precoz fueron más frecuentes en el grupo expuesto (p<0,005). Las dimensiones del desarrollo cognitivo, motor y lenguaje fueron normales en ambos grupos. Los expuestos al subtipo subcorionitis obtuvieron menor desempeño en las tres dimensiones. La corioamnionitis histológica no mostró influencia sobre el neurodesarrollo en prematuros menores de 34 semanas a los 2 años de edad. Se recomienda estudios longitudinales y multicéntricos para definir los efectos a largo plazo.

Published
2023

6. Structure and Content of the Entamoeba histolytica Genome

Author

Clark, C.G., primary, Alsmark, U.C.M., additional, Tazreiter, M., additional, Saito‐Nakano, Y., additional, Ali, V., additional, Marion, S., additional, Weber, C., additional, Mukherjee, C., additional, Bruchhaus, I., additional, Tannich, E., additional, Leippe, M., additional, Sicheritz‐Ponten, T., additional, Foster, P.G., additional, Samuelson, J., additional, Noël, C.J., additional, Hirt, R.P., additional, Embley, T.M., additional, Gilchrist, C.A., additional, Mann, B.J., additional, Singh, U., additional, Ackers, J.P., additional, Bhattacharya, S., additional, Bhattacharya, A., additional, Lohia, A., additional, Guillén, N., additional, Duchêne, M., additional, Nozaki, T., additional, and Hall, N., additional

Published
2007
Full Text
View/download PDF

7. Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP)

Author

Vincent, J. -L., Lefrant, J. -Y., Kotfis, K., Nanchal, R., Martin-Loeches, I., Wittebole, X., Sakka, S. G., Pickkers, P., Moreno, R., Sakr, Y., Pavlik, P., Manak, J., Kieslichova, E., Turek, R., Fischer, M., Valkova, R., Dadak, L., Dostal, P., Malaska, J., Hajek, R., Židková, A., Lavicka, P., Medve, L., Sarkany, A., Kremer, I., Marjanek, Z., Tamasi, P., Kolbusz, J., Kübler, A., Mielczarek, B., Mikaszewska-Sokolewicz, M., Tamowicz, B., Sulkowski, W., Smuszkiewicz, P., Pihowicz, A., Trejnowska, E., Hagau, N., Filipescu, D., Droc, G., Lupu, M., Nica, A., Stoica, R., Tomescu, D., Constantinescu, D., Valcoreanu Zbaganu, G., Slavcovici, A., Soskic, L., Palibrk, I., Jankovic, R., Jovanovic, B., Pandurovic, M., Bumbasirevic, V., Uljarevic, B., Surbatovic, M., Ladjevic, N., Slobodianiuk, G., Sobona, V., Cikova, A., Gebhardtova, A., Cohen, J., Sold, O., Urbanek, P., Schlieber, J., Reisinger, J., Auer, J., Hartjes, A., Lerche, A., Janous, T., Kink, E., Krahulec, W., Smolle, K., Van Der Schueren, M., Thibo, P., Vanhoof, M., Ahmet, I., Philippe, G., Dufaye, P., Jacobs, O., Fraipont, V., Biston, P., Dive, A., Bouckaert, Y., Gilbert, E., Gressens, B., Pinck, E., Collin, V., Vincent, J. L., De Waele, J., Rimachi, R., Gusu, D., De Decker, K., Mandianga, K., Heytens, L., Herbert, S., Olivier, V., Vandenheede, W., Rogiers, P., Kolodzeike, P., Kruse, M., Andersen, T., Harjola, V., Saarinen, K., Leone, M., Durocher, A., Moulront, S., Lepape, A., Losser, M., Cabaret, P., Kalaitzis, E., Zogheib, E., Charve, P., Francois, B., Lefrant, J. Y., Beilouny, B., Forceville, X., Misset, B., Jacobs, F., Bernard, F., Payen, D., Wynckel, A., Castelain, V., Faure, A., Lavagne, P., Thierry, L., Moussa, M., Vieillard-Baron, A., Durand, M., Gainnier, M., Ichai, C., Arens, S., Hoffmann, C., Kaffarnik, M., Scharnofske, C., Voigt, I., Peckelsen, C., Weber, M., Gille, J., Lange, A., Schoser, G., Sablotzki, A., Jaschinski, U., Bluethgen, A., Vogel, F., Tscheu, A., Fuchs, T., Wattenberg, M., Helmes, T., Scieszka, S., Heintz, M., Sakka, S., Kohler, J., Fiedler, F., Danz, M., Riessen, R., Kerz, T., Kersten, A., Tacke, F., Marx, G., Volkert, T., Schmutz, A., Nierhaus, A., Kluge, S., Abel, P., Janosi, R., Utzolino, S., Bracht, H., Toussaint, S., Giannakou Peftoulidou, M., Myrianthefs, P., Armaganidis, A., Routsi, C., Xini, A., Mouloudi, E., Kokoris, I., Kyriazopoulos, G., Vlachos, S., Lavrentieva, A., Partala, P., Nakos, G., Barry, J., O’Leary, R., Motherway, C., Faheem, M., Dunne, E., Donnelly, M., Konrad, T., Bonora, E., Achilli, C., Rossi, S., Castiglione, G., Peris, A., Albanese, D., Stocchetti, N., Citerio, G., Mozzoni, L., Sisillo, E., De Negri, P., Savioli, M., Vecchiarelli, P., Puflea, F., Stankovic, V., Minoja, G., Montibeller, S., Calligaro, P., Sorrentino, R., Feri, M., Zambon, M., Colombaroli, E., Giarratano, A., Pellis, T., Capra, C., Antonelli, M., Gullo, A., Chelazzi, C., De Capraris, A., Patroniti, N., Girardis, M., Franchi, F., Berlot, G., Ponssen, H., Ten Cate, J., Bormans, L., Husada, S., Buise, M., Van Der Hoven, B., Reidinga, A., Kuiper, M., Kluge, G., Den Boer, S., Kesecioglu, J., Van Leeuwen, H., Flaatten, H., Mo, S., Branco, V., Rua, F., Lafuente, E., Sousa, M., Catorze, N., Barros, M., Pereira, L., Vintém De Oliveira, A., Gomes, J., Gaspar, I., Pereira, M., Cymbron, M., Dias, A., Almeida, E., Beirao, S., Serra, I., Ribeiro, R., Povoa, P., Faria, F., Costa-E-Silva, Z., Nóbrega, J., Fernandes, F., Gabriel, J., Voga, G., Rupnik, E., Kosec, L., Kerin Povšic, M., Osojnik, I., Tomic, V., Sinkovic, A., González, J., Zavala, E., Pérez Valenzuela, J., Marina, L., Vidal-Cortés, P., Posada, P., Ignacio Martin-Loeches, A., Muñoz Guillén, N., Palomar, M., Sole-Violan, J., Torres, A., Gonzalez Gallego, M., Aguilar, G., Montoiro Allué, R., Argüeso, M., Parejo, M., Palomo Navarro, M., Jose, A., Nin, N., Alvarez Lerma, F., Martinez, O., Tenza Lozano, E., Arenal López, S., Perez Granda, M., Moreno, S., Llubia, C., De La Fuente Martos, C., Gonzalez-Arenas, P., Llamas Fernández, N., Gil Rueda, B., Estruch Pons, I., Cruza, N., Maroto, F., Estella, A., Ferrer, A., Iglesias Fraile, L., Quindos, B., Quintano, A., Tebar, M., Cardinal, P., Reyes, A., Rodríguez, A., Abella, A., García Del Valle, S., Yus, S., Maseda, E., Berezo, J., Tejero Pedregosa, A., Laplaza, C., Ferrer, R., Rico-Feijoo, J., Rodríguez, M., Monedero, P., Eriksson, K., Lind, D., Chabanel, D., Zender, H., Heer, K., Frankenberger, B., Jakob, S., Haller, A., Mathew, S., Downes, R., Barrera Groba, C., Johnston, A., Meacher, R., Keays, R., Haji-Michael, P., Tyler, C., Ferguson, A., Jones, S., Tyl, D., Ball, A., Vogel, J., Booth, M., Downie, P., Watters, M., Brett, S., Garfield, M., Everett, L., Heenen, S., Dhir, S., Beardow, Z., Mostert, M., Brosnan, S., Pinto, N., Harris, S., Summors, A., Andrew, N., Rose, A., Appelboam, R., Davies, O., Vickers, E., Agarwal, B., Szakmany, T., Wimbush, S., Welters, I., Pearse, R., Hollands, R., Kirk-Bayley, J., Fletcher, N., Bray, B., Brealey, D., Delle Karth, G., Draxler, V., Filzwieser, G., Heindl, W., Kellner, G., Lenz, K., Rossmann, E., Wiedermann, C., Chochrad, D., Damas, P., Decruyenaere, J., Hoste, E., Devriendt, J., Espeel, B., Installe, E., Malbrain, M., Nollet, G., Preiser, J. C., Raemaekers, J., Roman, A., Simon, M., Spapen, H., Swinnen, W., Vallot, F., Chytra, I., Herold, I., Polak, F., Sterba, M., Bestle, M., Espersen, K., Guldager, H., Welling, K. -L., Nyman, D., Ruokonen, E., Annane, D., Catogni, P., Colas, G., Coulomb, F., Dorne, R., Garrouste, M., Isetta, C., Larché, J., LeGall, J. -R., Lessire, H., Malledant, Y., Mateu, P., Ossart, M., Schlossmacher, P., Timsit, J. -F., Winnock, S., Sollet, J. -P., Mallet, L., Maurer, P., Sab, J. M., Sollet, J. P., Aykut, G., Brunkhorst, F., Lauterbach, M., Ragaller, M., Gatz, R., Gerlach, H., Henzler, D., Hopf, H. -B., Hueneburg, H., Karzai, W., Keller, A., Bauer, T., Kuhlmann, U., Langgartner, J., Manhold, C., Reith, B., Schuerholz, T., Spies, C., Stögbauer, R., Unterburger, J., Clouva-Molyvdas, P. -M., Giokas, G., Ioannidou, E., Lahana, A., Liolios, A., Marathias, K., Tasiou, A., Tsangaris, H., Marsh, B., Power, M., Sprung, C., Biagioli, B., Bobbio Pallavicini, F., Pesenti, A., Della Corte, F., Donadio, P. P., Donati, A., Giorgio, T., Giudici, D., Greco, S., Guadagnucci, A., Lapichino, G., Livigni, S., Moise, G., Nardi, G., Panascia, E., Pizzamiglio, M., Ranieri, V. M., Rosi, R., Sicignano, A., Solca, M., Vignali, G., Volpe Rinonapoli, I., Barnas, M., De Bel, E. E., De Pont, A. -C., Groeneveld, J., Nijsten, M., Sie, L., Zandstra, D. F., Harboe, S., Lindén, S., Lovstad, R. Z., Moen, H., Smith-Erichsen, N., Piotrowski, A., Karpel, E., Pais-De-Lacerda, A., Paiva, J. A., Pimentel, A., Jovanovic, K., Malik, P., Lucka, K., Aldecoa Alvarez-Santullano, C., Artigas, A., Escorsell, A., Nicolas, J., Izura Cea, J. J., Montejo, J., Palencia, E., Santos, F., Sierra-Camerino, R., Sipmann, F., Brodersen, K., Haggqvist, J., Hermansson, D., Hjelmqvist, H., Loderer, G., Maggiorini, M., Andrews, P., Appadu, B., Bewley, J., Burchett, K., Chambers, P., Coakley, J., Doberenz, D., Eastwood, N., Fielden, J., Gedney, J., Gunning, K., Harling, D., Jankowski, S., Jayson, D., Kilner, A., Krishna-Kumar, V., Lei, K., Mackenzie, S., Macnaughton, P., McCulloch, C., Morgan, P., Rhodes, A., Roberts, C., Russell, M., Tupper-Carey, D., Wright, M., Twohey, L., Watts, J., Webster, R., Williams, D., on behalf of the ICON and SOAP investigators and SOAP investigators, Vincent, J.-L., Lefrant, J.-Y., Kotfis, K., Nanchal, R., Martin-Loeches, I., Wittebole, X., Sakka, S.G., Pickkers, P., Moreno, R., Sakr, Y., Pavlik, P., Manak, J., Kieslichova, E., Turek, R., Fischer, M., Valkova, R., Dadak, L., Dostal, P., Malaska, J., Hajek, R., Židková, A., Lavicka, P., Medve, L., Sarkany, A., Kremer, I., Marjanek, Z., Tamasi, P., Kolbusz, J., Kübler, A., Mielczarek, B., Mikaszewska-Sokolewicz, M., Tamowicz, B., Sulkowski, W., Smuszkiewicz, P., Pihowicz, A., Trejnowska, E., Hagau, N., Filipescu, D., Droc, G., Lupu, M., Nica, A., Stoica, R., Tomescu, D., Constantinescu, D., Valcoreanu Zbaganu, G., Slavcovici, A., Soskic, L., Palibrk, I., Jankovic, R., Jovanovic, B., Pandurovic, M., Bumbasirevic, V., Uljarevic, B., Surbatovic, M., Ladjevic, N., Slobodianiuk, G., Sobona, V., Cikova, A., Gebhardtova, A., Cohen, J., Sold, O., Urbanek, P., Schlieber, J., Reisinger, J., Auer, J., Hartjes, A., Lerche, A., Janous, T., Kink, E., Krahulec, W., Smolle, K., Van Der Schueren, M., Thibo, P., Vanhoof, M., Ahmet, I., Philippe, G., Dufaye, P., Jacobs, O., Fraipont, V., Biston, P., Dive, A., Bouckaert, Y., Gilbert, E., Gressens, B., Pinck, E., Collin, V., Vincent, J.L., De Waele, J., Rimachi, R., Gusu, D., De Decker, K., Mandianga, K., Heytens, L., Herbert, S., Olivier, V., Vandenheede, W., Rogiers, P., Kolodzeike, P., Kruse, M., Andersen, T., Harjola, V., Saarinen, K., Leone, M., Durocher, A., Moulront, S., Lepape, A., Losser, M., Cabaret, P., Kalaitzis, E., Zogheib, E., Charve, P., Francois, B., Lefrant, J.Y., Beilouny, B., Forceville, X., Misset, B., Jacobs, F., Bernard, F., Payen, D., Wynckel, A., Castelain, V., Faure, A., Lavagne, P., Thierry, L., Moussa, M., Vieillard-Baron, A., Durand, M., Gainnier, M., Ichai, C., Arens, S., Hoffmann, C., Kaffarnik, M., Scharnofske, C., Voigt, I., Peckelsen, C., Weber, M., Gille, J., Lange, A., Schoser, G., Sablotzki, A., Jaschinski, U., Bluethgen, A., Vogel, F., Tscheu, A., Fuchs, T., Wattenberg, M., Helmes, T., Scieszka, S., Heintz, M., Sakka, S., Kohler, J., Fiedler, F., Danz, M., Riessen, R., Kerz, T., Kersten, A., Tacke, F., Marx, G., Volkert, T., Schmutz, A., Nierhaus, A., Kluge, S., Abel, P., Janosi, R., Utzolino, S., Bracht, H., Toussaint, S., Giannakou Peftoulidou, M., Myrianthefs, P., Armaganidis, A., Routsi, C., Xini, A., Mouloudi, E., Kokoris, I., Kyriazopoulos, G., Vlachos, S., Lavrentieva, A., Partala, P., Nakos, G., Barry, J., O’Leary, R., Motherway, C., Faheem, M., Dunne, E., Donnelly, M., Konrad, T., Bonora, E., Achilli, C., Rossi, S., Castiglione, G., Peris, A., Albanese, D., Stocchetti, N., Citerio, G., Mozzoni, L., Sisillo, E., De Negri, P., Savioli, M., Vecchiarelli, P., Puflea, F., Stankovic, V., Minoja, G., Montibeller, S., Calligaro, P., Sorrentino, R., Feri, M., Zambon, M., Colombaroli, E., Giarratano, A., Pellis, T., Capra, C., Antonelli, M., Gullo, A., Chelazzi, C., De Capraris, A., Patroniti, N., Girardis, M., Franchi, F., Berlot, G., Ponssen, H., Ten Cate, J., Bormans, L., Husada, S., Buise, M., Van Der Hoven, B., Reidinga, A., Kuiper, M., Kluge, G., Den Boer, S., Kesecioglu, J., Van Leeuwen, H., Flaatten, H., Mo, S., Branco, V., Rua, F., Lafuente, E., Sousa, M., Catorze, N., Barros, M., Pereira, L., Vintém De Oliveira, A., Gomes, J., Gaspar, I., Pereira, M., Cymbron, M., Dias, A., Almeida, E., Beirao, S., Serra, I., Ribeiro, R., Povoa, P., Faria, F., Costa-E-Silva, Z., Nóbrega, J., Fernandes, F., Gabriel, J., Voga, G., Rupnik, E., Kosec, L., Kerin Povšic, M., Osojnik, I., Tomic, V., Sinkovic, A., González, J., Zavala, E., Pérez Valenzuela, J., Marina, L., Vidal-Cortés, P., Posada, P., Ignacio Martin-Loeches, A., Muñoz Guillén, N., Palomar, M., Sole-Violan, J., Torres, A., Gonzalez Gallego, M., Aguilar, G., Montoiro Allué, R., Argüeso, M., Parejo, M., Palomo Navarro, M., Jose, A., Nin, N., Alvarez Lerma, F., Martinez, O., Tenza Lozano, E., Arenal López, S., Perez Granda, M., Moreno, S., Llubia, C., De La Fuente Martos, C., Gonzalez-Arenas, P., Llamas Fernández, N., Gil Rueda, B., Estruch Pons, I., Cruza, N., Maroto, F., Estella, A., Ferrer, A., Iglesias Fraile, L., Quindos, B., Quintano, A., Tebar, M., Cardinal, P., Reyes, A., Rodríguez, A., Abella, A., García Del Valle, S., Yus, S., Maseda, E., Berezo, J., Tejero Pedregosa, A., Laplaza, C., Ferrer, R., Rico-Feijoo, J., Rodríguez, M., Monedero, P., Eriksson, K., Lind, D., Chabanel, D., Zender, H., Heer, K., Frankenberger, B., Jakob, S., Haller, A., Mathew, S., Downes, R., Barrera Groba, C., Johnston, A., Meacher, R., Keays, R., Haji-Michael, P., Tyler, C., Ferguson, A., Jones, S., Tyl, D., Ball, A., Vogel, J., Booth, M., Downie, P., Watters, M., Brett, S., Garfield, M., Everett, L., Heenen, S., Dhir, S., Beardow, Z., Mostert, M., Brosnan, S., Pinto, N., Harris, S., Summors, A., Andrew, N., Rose, A., Appelboam, R., Davies, O., Vickers, E., Agarwal, B., Szakmany, T., Wimbush, S., Welters, I., Pearse, R., Hollands, R., Kirk-Bayley, J., Fletcher, N., Bray, B., Brealey, D., Delle Karth, G., Draxler, V., Filzwieser, G., Heindl, W., Kellner, G., Lenz, K., Rossmann, E., Wiedermann, C., Chochrad, D., Damas, P., Decruyenaere, J., Hoste, E., Devriendt, J., Espeel, B., Installe, E., Malbrain, M., Nollet, G., Preiser, J.C., Raemaekers, J., Roman, A., Simon, M., Spapen, H., Swinnen, W., Vallot, F., Chytra, I., Herold, I., Polak, F., Sterba, M., Bestle, M., Espersen, K., Guldager, H., Welling, K.-L., Nyman, D., Ruokonen, E., Annane, D., Catogni, P., Colas, G., Coulomb, F., Dorne, R., Garrouste, M., Isetta, C., Larché, J., LeGall, J.-R., Lessire, H., Malledant, Y., Mateu, P., Ossart, M., Schlossmacher, P., Timsit, J.-F., Winnock, S., Sollet, J.-P., Mallet, L., Maurer, P., Sab, J.M., Sollet, J.P., Aykut, G., Brunkhorst, F., Lauterbach, M., Ragaller, M., Gatz, R., Gerlach, H., Henzler, D., Hopf, H.-B., Hueneburg, H., Karzai, W., Keller, A., Bauer, T., Kuhlmann, U., Langgartner, J., Manhold, C., Reith, B., Schuerholz, T., Spies, C., Stögbauer, R., Unterburger, J., Clouva-Molyvdas, P.-M., Giokas, G., Ioannidou, E., Lahana, A., Liolios, A., Marathias, K., Tasiou, A., Tsangaris, H., Marsh, B., Power, M., Sprung, C., Biagioli, B., Bobbio Pallavicini, F., Pesenti, A., Della Corte, F., Donadio, P.P., Donati, A., Giorgio, T., Giudici, D., Greco, S., Guadagnucci, A., Lapichino, G., Livigni, S., Moise, G., Nardi, G., Panascia, E., Pizzamiglio, M., Ranieri, V.M., Rosi, R., Sicignano, A., Solca, M., Vignali, G., Volpe Rinonapoli, I., Barnas, M., De Bel, E.E., De Pont, A.-C., Groeneveld, J., Nijsten, M., Sie, L., Zandstra, D.F., Harboe, S., Lindén, S., Lovstad, R.Z., Moen, H., Smith-Erichsen, N., Piotrowski, A., Karpel, E., Pais-De-Lacerda, A., Paiva, J.A., Pimentel, A., Jovanovic, K., Malik, P., Lucka, K., Aldecoa Alvarez-Santullano, C., Artigas, A., Escorsell, A., Nicolas, J., Izura Cea, J.J., Montejo, J., Palencia, E., Santos, F., Sierra-Camerino, R., Sipmann, F., Brodersen, K., Haggqvist, J., Hermansson, D., Hjelmqvist, H., Loderer, G., Maggiorini, M., Andrews, P., Appadu, B., Bewley, J., Burchett, K., Chambers, P., Coakley, J., Doberenz, D., Eastwood, N., Fielden, J., Gedney, J., Gunning, K., Harling, D., Jankowski, S., Jayson, D., Kilner, A., Krishna-Kumar, V., Lei, K., Mackenzie, S., Macnaughton, P., McCulloch, C., Morgan, P., Rhodes, A., Roberts, C., Russell, M., Tupper-Carey, D., Wright, M., Twohey, L., Watts, J., Webster, R., Williams, D., on behalf of the ICON and SOAP investigators and SOAP investigators, Université libre de Bruxelles (ULB), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), Université Montpellier 1 (UM1)-Université de Montpellier (UM), University of Wisconsin School of Medicine and Public Health, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Cliniques universitaires St Luc [Bruxelles], University Hospital of Cologne [Cologne], Radboud university [Nijmegen], Centro Hospitalar de Lisboa Central E.P.E, Intensive Care, Vincent, J, Lefrant, J, Kotfis, K, Nanchal, R, Martin-Loeches, I, Wittebole, X, Sakka, S, Pickkers, P, Moreno, R, Sakr, Y, Pavlik, P, Manak, J, Kieslichova, E, Turek, R, Fischer, M, Valkova, R, Dadak, L, Dostal, P, Malaska, J, Hajek, R, Zidkova, A, Lavicka, P, Medve, L, Sarkany, A, Kremer, I, Marjanek, Z, Tamasi, P, Kolbusz, J, Kubler, A, Mielczarek, B, Mikaszewska-Sokolewicz, M, Tamowicz, B, Sulkowski, W, Smuszkiewicz, P, Pihowicz, A, Trejnowska, E, Hagau, N, Filipescu, D, Droc, G, Lupu, M, Nica, A, Stoica, R, Tomescu, D, Constantinescu, D, Valcoreanu Zbaganu, G, Slavcovici, A, Soskic, L, Palibrk, I, Jankovic, R, Jovanovic, B, Pandurovic, M, Bumbasirevic, V, Uljarevic, B, Surbatovic, M, Ladjevic, N, Slobodianiuk, G, Sobona, V, Cikova, A, Gebhardtova, A, Cohen, J, Sold, O, Urbanek, P, Schlieber, J, Reisinger, J, Auer, J, Hartjes, A, Lerche, A, Janous, T, Kink, E, Krahulec, W, Smolle, K, Van Der Schueren, M, Thibo, P, Vanhoof, M, Ahmet, I, Philippe, G, Dufaye, P, Jacobs, O, Fraipont, V, Biston, P, Dive, A, Bouckaert, Y, Gilbert, E, Gressens, B, Pinck, E, Collin, V, De Waele, J, Rimachi, R, Gusu, D, De Decker, K, Mandianga, K, Heytens, L, Herbert, S, Olivier, V, Vandenheede, W, Rogiers, P, Kolodzeike, P, Kruse, M, Andersen, T, Harjola, V, Saarinen, K, Leone, M, Durocher, A, Moulront, S, Lepape, A, Losser, M, Cabaret, P, Kalaitzis, E, Zogheib, E, Charve, P, Francois, B, Beilouny, B, Forceville, X, Misset, B, Jacobs, F, Bernard, F, Payen, D, Wynckel, A, Castelain, V, Faure, A, Lavagne, P, Thierry, L, Moussa, M, Vieillard-Baron, A, Durand, M, Gainnier, M, Ichai, C, Arens, S, Hoffmann, C, Kaffarnik, M, Scharnofske, C, Voigt, I, Peckelsen, C, Weber, M, Gille, J, Lange, A, Schoser, G, Sablotzki, A, Jaschinski, U, Bluethgen, A, Vogel, F, Tscheu, A, Fuchs, T, Wattenberg, M, Helmes, T, Scieszka, S, Heintz, M, Kohler, J, Fiedler, F, Danz, M, Riessen, R, Kerz, T, Kersten, A, Tacke, F, Marx, G, Volkert, T, Schmutz, A, Nierhaus, A, Kluge, S, Abel, P, Janosi, R, Utzolino, S, Bracht, H, Toussaint, S, Giannakou Peftoulidou, M, Myrianthefs, P, Armaganidis, A, Routsi, C, Xini, A, Mouloudi, E, Kokoris, I, Kyriazopoulos, G, Vlachos, S, Lavrentieva, A, Partala, P, Nakos, G, Barry, J, O'Leary, R, Motherway, C, Faheem, M, Dunne, E, Donnelly, M, Konrad, T, Bonora, E, Achilli, C, Rossi, S, Castiglione, G, Peris, A, Albanese, D, Stocchetti, N, Citerio, G, Mozzoni, L, Sisillo, E, De Negri, P, Savioli, M, Vecchiarelli, P, Puflea, F, Stankovic, V, Minoja, G, Montibeller, S, Calligaro, P, Sorrentino, R, Feri, M, Zambon, M, Colombaroli, E, Giarratano, A, Pellis, T, Capra, C, Antonelli, M, Gullo, A, Chelazzi, C, De Capraris, A, Patroniti, N, Girardis, M, Franchi, F, Berlot, G, Ponssen, H, Ten Cate, J, Bormans, L, Husada, S, Buise, M, Van Der Hoven, B, Reidinga, A, Kuiper, M, Kluge, G, Den Boer, S, Kesecioglu, J, Van Leeuwen, H, Flaatten, H, Mo, S, Branco, V, Rua, F, Lafuente, E, Sousa, M, Catorze, N, Barros, M, Pereira, L, Vintem De Oliveira, A, Gomes, J, Gaspar, I, Pereira, M, Cymbron, M, Dias, A, Almeida, E, Beirao, S, Serra, I, Ribeiro, R, Povoa, P, Faria, F, Costa-E-Silva, Z, Nobrega, J, Fernandes, F, Gabriel, J, Voga, G, Rupnik, E, Kosec, L, Kerin Povsic, M, Osojnik, I, Tomic, V, Sinkovic, A, Gonzalez, J, Zavala, E, Perez Valenzuela, J, Marina, L, Vidal-Cortes, P, Posada, P, Ignacio Martin-Loeches, A, Munoz Guillen, N, Palomar, M, Sole-Violan, J, Torres, A, Gonzalez Gallego, M, Aguilar, G, Montoiro Allue, R, Argueso, M, Parejo, M, Palomo Navarro, M, Jose, A, Nin, N, Alvarez Lerma, F, Martinez, O, Tenza Lozano, E, Arenal Lopez, S, Perez Granda, M, Moreno, S, Llubia, C, De La Fuente Martos, C, Gonzalez-Arenas, P, Llamas Fernandez, N, Gil Rueda, B, Estruch Pons, I, Cruza, N, Maroto, F, Estella, A, Ferrer, A, Iglesias Fraile, L, Quindos, B, Quintano, A, Tebar, M, Cardinal, P, Reyes, A, Rodriguez, A, Abella, A, Garcia Del Valle, S, Yus, S, Maseda, E, Berezo, J, Tejero Pedregosa, A, Laplaza, C, Ferrer, R, Rico-Feijoo, J, Rodriguez, M, Monedero, P, Eriksson, K, Lind, D, Chabanel, D, Zender, H, Heer, K, Frankenberger, B, Jakob, S, Haller, A, Mathew, S, Downes, R, Barrera Groba, C, Johnston, A, Meacher, R, Keays, R, Haji-Michael, P, Tyler, C, Ferguson, A, Jones, S, Tyl, D, Ball, A, Vogel, J, Booth, M, Downie, P, Watters, M, Brett, S, Garfield, M, Everett, L, Heenen, S, Dhir, S, Beardow, Z, Mostert, M, Brosnan, S, Pinto, N, Harris, S, Summors, A, Andrew, N, Rose, A, Appelboam, R, Davies, O, Vickers, E, Agarwal, B, Szakmany, T, Wimbush, S, Welters, I, Pearse, R, Hollands, R, Kirk-Bayley, J, Fletcher, N, Bray, B, Brealey, D, Delle Karth, G, Draxler, V, Filzwieser, G, Heindl, W, Kellner, G, Lenz, K, Rossmann, E, Wiedermann, C, Chochrad, D, Damas, P, Decruyenaere, J, Hoste, E, Devriendt, J, Espeel, B, Installe, E, Malbrain, M, Nollet, G, Preiser, J, Raemaekers, J, Roman, A, Simon, M, Spapen, H, Swinnen, W, Vallot, F, Chytra, I, Herold, I, Polak, F, Sterba, M, Bestle, M, Espersen, K, Guldager, H, Welling, K, Nyman, D, Ruokonen, E, Annane, D, Catogni, P, Colas, G, Coulomb, F, Dorne, R, Garrouste, M, Isetta, C, Larche, J, Legall, J, Lessire, H, Malledant, Y, Mateu, P, Ossart, M, Schlossmacher, P, Timsit, J, Winnock, S, Sollet, J, Mallet, L, Maurer, P, Sab, J, Aykut, G, Brunkhorst, F, Lauterbach, M, Ragaller, M, Gatz, R, Gerlach, H, Henzler, D, Hopf, H, Hueneburg, H, Karzai, W, Keller, A, Bauer, T, Kuhlmann, U, Langgartner, J, Manhold, C, Reith, B, Schuerholz, T, Spies, C, Stogbauer, R, Unterburger, J, Clouva-Molyvdas, P, Giokas, G, Ioannidou, E, Lahana, A, Liolios, A, Marathias, K, Tasiou, A, Tsangaris, H, Marsh, B, Power, M, Sprung, C, Biagioli, B, Bobbio Pallavicini, F, Pesenti, A, Della Corte, F, Donadio, P, Donati, A, Giorgio, T, Giudici, D, Greco, S, Guadagnucci, A, Lapichino, G, Livigni, S, Moise, G, Nardi, G, Panascia, E, Pizzamiglio, M, Ranieri, V, Rosi, R, Sicignano, A, Solca, M, Vignali, G, Volpe Rinonapoli, I, Barnas, M, De Bel, E, De Pont, A, Groeneveld, J, Nijsten, M, Sie, L, Zandstra, D, Harboe, S, Linden, S, Lovstad, R, Moen, H, Smith-Erichsen, N, Piotrowski, A, Karpel, E, Pais-De-Lacerda, A, Paiva, J, Pimentel, A, Jovanovic, K, Malik, P, Lucka, K, Aldecoa Alvarez-Santullano, C, Artigas, A, Escorsell, A, Nicolas, J, Izura Cea, J, Montejo, J, Palencia, E, Santos, F, Sierra-Camerino, R, Sipmann, F, Brodersen, K, Haggqvist, J, Hermansson, D, Hjelmqvist, H, Loderer, G, Maggiorini, M, Andrews, P, Appadu, B, Bewley, J, Burchett, K, Chambers, P, Coakley, J, Doberenz, D, Eastwood, N, Fielden, J, Gedney, J, Gunning, K, Harling, D, Jankowski, S, Jayson, D, Kilner, A, Krishna-Kumar, V, Lei, K, Mackenzie, S, Macnaughton, P, Mcculloch, C, Morgan, P, Rhodes, A, Roberts, C, Russell, M, Tupper-Carey, D, Wright, M, Twohey, L, Watts, J, Webster, R, Williams, D, Supporting clinical sciences, Other departments, CHU Lille, Université de Lille, Unité de réanimation médicale [CHU de Carémeau, Nîmes], West Pomeranian University of Technology Szczecin, Universität Witten Herdecke, Radboud University [Nijmegen], Faculdade de Medicina de São José do Rio Preto [FAMERP], Jena University Hospital [Jena], Vincent, J. -L., Lefrant, J. -Y., Sakka, S. G., Zidkova, A., Kubler, A., O'Leary, R., Vintem De Oliveira, A., Nobrega, J., Kerin Povsic, M., Gonzalez, J., Perez Valenzuela, J., Vidal-Cortes, P., Munoz Guillen, N., Montoiro Allue, R., Argueso, M., Arenal Lopez, S., Llamas Fernandez, N., Rodriguez, A., Garcia Del Valle, S., Rodriguez, M., Preiser, J. C., Welling, K. -L., Larche, J., Legall, J. -R., Timsit, J. -F., Sollet, J. -P., Sab, J. M., Hopf, H. -B., Stogbauer, R., Clouva-Molyvdas, P. -M., Donadio, P. P., Ranieri, V. M., De Bel, E. E., De Pont, A. -C., Zandstra, D. F., Linden, S., Lovstad, R. Z., Paiva, J. A., Izura Cea, J. J., Mcculloch, C., Vincent J.-L., Lefrant J.-Y., Kotfis K., Nanchal R., Martin-Loeches I., Wittebole X., Sakka S.G., Pickkers P., Moreno R., Sakr Y., Pavlik P., Manak J., Kieslichova E., Turek R., Fischer M., Valkova R., Dadak L., Dostal P., Malaska J., Hajek R., Zidkova A., Lavicka P., Medve L., Sarkany A., Kremer I., Marjanek Z., Tamasi P., Kolbusz J., Kubler A., Mielczarek B., Mikaszewska-Sokolewicz M., Tamowicz B., Sulkowski W., Smuszkiewicz P., Pihowicz A., Trejnowska E., Hagau N., Filipescu D., Droc G., Lupu M., Nica A., Stoica R., Tomescu D., Constantinescu D., Valcoreanu Zbaganu G., Slavcovici A., Soskic L., Palibrk I., Jankovic R., Jovanovic B., Pandurovic M., Bumbasirevic V., Uljarevic B., Surbatovic M., Ladjevic N., Slobodianiuk G., Sobona V., Cikova A., Gebhardtova A., Cohen J., Sold O., Urbanek P., Schlieber J., Reisinger J., Auer J., Hartjes A., Lerche A., Janous T., Kink E., Krahulec W., Smolle K., Van Der Schueren M., Thibo P., Vanhoof M., Ahmet I., Philippe G., Dufaye P., Jacobs O., Fraipont V., Biston P., Dive A., Bouckaert Y., Gilbert E., Gressens B., Pinck E., Collin V., De Waele J., Rimachi R., Gusu D., De Decker K., Mandianga K., Heytens L., Herbert S., Olivier V., Vandenheede W., Rogiers P., Kolodzeike P., Kruse M., Andersen T., Harjola V., Saarinen K., Leone M., Durocher A., Moulront S., Lepape A., Losser M., Cabaret P., Kalaitzis E., Zogheib E., Charve P., Francois B., Beilouny B., Forceville X., Misset B., Jacobs F., Bernard F., Payen D., Wynckel A., Castelain V., Faure A., Lavagne P., Thierry L., Moussa M., Vieillard-Baron A., Durand M., Gainnier M., Ichai C., Arens S., Hoffmann C., Kaffarnik M., Scharnofske C., Voigt I., Peckelsen C., Weber M., Gille J., Lange A., Schoser G., Sablotzki A., Jaschinski U., Bluethgen A., Vogel F., Tscheu A., Fuchs T., Wattenberg M., Helmes T., Scieszka S., Heintz M., Sakka S., Kohler J., Fiedler F., Danz M., Riessen R., Kerz T., Kersten A., Tacke F., Marx G., Volkert T., Schmutz A., Nierhaus A., Kluge S., Abel P., Janosi R., Utzolino S., Bracht H., Toussaint S., Giannakou Peftoulidou M., Myrianthefs P., Armaganidis A., Routsi C., Xini A., Mouloudi E., Kokoris I., Kyriazopoulos G., Vlachos S., Lavrentieva A., Partala P., Nakos G., Barry J., O'Leary R., Motherway C., Faheem M., Dunne E., Donnelly M., Konrad T., Bonora E., Achilli C., Rossi S., Castiglione G., Peris A., Albanese D., Stocchetti N., Citerio G., Mozzoni L., Sisillo E., De Negri P., Savioli M., Vecchiarelli P., Puflea F., Stankovic V., Minoja G., Montibeller S., Calligaro P., Sorrentino R., Feri M., Zambon M., Colombaroli E., Giarratano A., Pellis T., Capra C., Antonelli M., Gullo A., Chelazzi C., De Capraris A., Patroniti N., Girardis M., Franchi F., Berlot G., Ponssen H., Ten Cate J., Bormans L., Husada S., Buise M., Van Der Hoven B., Reidinga A., Kuiper M., Kluge G., Den Boer S., Kesecioglu J., Van Leeuwen H., Flaatten H., Mo S., Branco V., Rua F., Lafuente E., Sousa M., Catorze N., Barros M., Pereira L., Vintem De Oliveira A., Gomes J., Gaspar I., Pereira M., Cymbron M., Dias A., Almeida E., Beirao S., Serra I., Ribeiro R., Povoa P., Faria F., Costa-E-Silva Z., Nobrega J., Fernandes F., Gabriel J., Voga G., Rupnik E., Kosec L., Kerin Povsic M., Osojnik I., Tomic V., Sinkovic A., Gonzalez J., Zavala E., Perez Valenzuela J., Marina L., Vidal-Cortes P., Posada P., Ignacio Martin-Loeches A., Munoz Guillen N., Palomar M., Sole-Violan J., Torres A., Gonzalez Gallego M., Aguilar G., Montoiro Allue R., Argueso M., Parejo M., Palomo Navarro M., Jose A., Nin N., Alvarez Lerma F., Martinez O., Tenza Lozano E., Arenal Lopez S., Perez Granda M., Moreno S., Llubia C., De La Fuente Martos C., Gonzalez-Arenas P., Llamas Fernandez N., Gil Rueda B., Estruch Pons I., Cruza N., Maroto F., Estella A., Ferrer A., Iglesias Fraile L., Quindos B., Quintano A., Tebar M., Cardinal P., Reyes A., Rodriguez A., Abella A., Garcia Del Valle S., Yus S., Maseda E., Berezo J., Tejero Pedregosa A., Laplaza C., Ferrer R., Rico-Feijoo J., Rodriguez M., Monedero P., Eriksson K., Lind D., Chabanel D., Zender H., Heer K., Frankenberger B., Jakob S., Haller A., Mathew S., Downes R., Barrera Groba C., Johnston A., Meacher R., Keays R., Haji-Michael P., Tyler C., Ferguson A., Jones S., Tyl D., Ball A., Vogel J., Booth M., Downie P., Watters M., Brett S., Garfield M., Everett L., Heenen S., Dhir S., Beardow Z., Mostert M., Brosnan S., Pinto N., Harris S., Summors A., Andrew N., Rose A., Appelboam R., Davies O., Vickers E., Agarwal B., Szakmany T., Wimbush S., Welters I., Pearse R., Hollands R., Kirk-Bayley J., Fletcher N., Bray B., Brealey D., Delle Karth G., Draxler V., Filzwieser G., Heindl W., Kellner G., Lenz K., Rossmann E., Wiedermann C., Chochrad D., Damas P., Decruyenaere J., Hoste E., Devriendt J., Espeel B., Installe E., Malbrain M., Nollet G., Preiser J.C., Raemaekers J., Roman A., Simon M., Spapen H., Swinnen W., Vallot F., Chytra I., Herold I., Polak F., Sterba M., Bestle M., Espersen K., Guldager H., Welling K.-L., Nyman D., Ruokonen E., Annane D., Catogni P., Colas G., Coulomb F., Dorne R., Garrouste M., Isetta C., Larche J., LeGall J.-R., Lessire H., Malledant Y., Mateu P., Ossart M., Schlossmacher P., Timsit J.-F., Winnock S., Sollet J.-P., Mallet L., Maurer P., Sab J.M., Aykut G., Brunkhorst F., Lauterbach M., Ragaller M., Gatz R., Gerlach H., Henzler D., Hopf H.-B., Hueneburg H., Karzai W., Keller A., Bauer T., Kuhlmann U., Langgartner J., Manhold C., Reith B., Schuerholz T., Spies C., Stogbauer R., Unterburger J., Clouva-Molyvdas P.-M., Giokas G., Ioannidou E., Lahana A., Liolios A., Marathias K., Tasiou A., Tsangaris H., Marsh B., Power M., Sprung C., Biagioli B., Bobbio Pallavicini F., Pesenti A., Della Corte F., Donadio P.P., Donati A., Giorgio T., Giudici D., Greco S., Guadagnucci A., Lapichino G., Livigni S., Moise G., Nardi G., Panascia E., Pizzamiglio M., Ranieri V.M., Rosi R., Sicignano A., Solca M., Vignali G., Volpe Rinonapoli I., Barnas M., De Bel E.E., De Pont A.-C., Groeneveld J., Nijsten M., Sie L., Zandstra D.F., Harboe S., Linden S., Lovstad R.Z., Moen H., Smith-Erichsen N., Piotrowski A., Karpel E., Pais-De-Lacerda A., Paiva J.A., Pimentel A., Jovanovic K., Malik P., Lucka K., Aldecoa Alvarez-Santullano C., Artigas A., Escorsell A., Nicolas J., Izura Cea J.J., Montejo J., Palencia E., Santos F., Sierra-Camerino R., Sipmann F., Brodersen K., Haggqvist J., Hermansson D., Hjelmqvist H., Loderer G., Maggiorini M., Andrews P., Appadu B., Bewley J., Burchett K., Chambers P., Coakley J., Doberenz D., Eastwood N., Fielden J., Gedney J., Gunning K., Harling D., Jankowski S., Jayson D., Kilner A., Krishna-Kumar V., Lei K., Mackenzie S., Macnaughton P., McCulloch C., Morgan P., Rhodes A., Roberts C., Russell M., Tupper-Carey D., Wright M., Twohey L., Watts J., Webster R., and Williams D.

Subjects
Male, Original, Epidemiology, [SDV]Life Sciences [q-bio], HSJ UCI, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], MULTICENTER, clinical outcome, mortality rate, Critical Care and Intensive Care Medicine, intensive care unit, law.invention, 0302 clinical medicine, Severity of disease, law, middle aged, Medicine and Health Sciences, FAILURE, 030212 general & internal medicine, Hospital Mortality, intensive care units -- analysis -- epidemiology -- mortality, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), CODES, comparative study, intensive care, Medicine(all), multilevel analysi, Incidence, adult, Sciences bio-médicales et agricoles, Intensive care unit, 3. Good health, Europe, sepsa, Intensive Care Units, female, Cohort, enote intenzivne terapije -- analiza -- epidemiologija -- umrljivost, Human, Adult, medicine.medical_specialty, severity of disease, Critical Care, Sepsi, Intensive Care Unit, UNITED-STATES, 610 Medicine & health, INTENSIVE-CARE, European, Article, Sepsis, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, length of stay, male, Humans, Length of Stay, Anesthesiology, Intensive care, SCORE, medicine, udc:614.2, human, outcome assessment, Septic shock, business.industry, SEPTIC SHOCK, 030208 emergency & critical care medicine, medicine.disease, TRENDS, major clinical study, SEVERE SEPSIS, comorbidity assessment, Emergency medicine, Observational study, CLAIMS, business, resnost bolezni
Abstract

Purpose: To evaluate differences in the characteristics and outcomes of intensive care unit (ICU) patients over time. Methods: We reviewed all epidemiological data, including comorbidities, types and severity of organ failure, interventions, lengths of stay and outcome, for patients from the Sepsis Occurrence in Acutely ill Patients (SOAP) study, an observational study conducted in European intensive care units in 2002, and the Intensive Care Over Nations (ICON) audit, a survey of intensive care unit patients conducted in 2012. Results: We compared the 3147 patients from the SOAP study with the 4852 patients from the ICON audit admitted to intensive care units in the same countries as those in the SOAP study. The ICON patients were older (62.5 ± 17.0 vs. 60.6 ± 17.4 years) and had higher severity scores than the SOAP patients. The proportion of patients with sepsis at any time during the intensive care unit stay was slightly higher in the ICON study (31.9 vs. 29.6%, p = 0.03). In multilevel analysis, the adjusted odds of ICU mortality were significantly lower for ICON patients than for SOAP patients, particularly in patients with sepsis [OR 0.45 (0.35–0.59), p < 0.001]. Conclusions: Over the 10-year period between 2002 and 2012, the proportion of patients with sepsis admitted to European ICUs remained relatively stable, but the severity of disease increased. In multilevel analysis, the odds of ICU mortality were lower in our 2012 cohort compared to our 2002 cohort, particularly in patients with sepsis., 0, info:eu-repo/semantics/published

Published
2018

9. Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment

Author

Mamun Al Mahtab, Sheikh Mohammad Fazle Akbar, Julio Cesar Aguilar, Osamu Yoshida, Sakirul Khan, Guillen Nieto Gerardo, and Yoichi Hiasa

Subjects
chronic hepatitis B, NASVAC, immune therapy, nasal therapeutic vaccine, 5-year follow-up, Medicine (General), R5-920
Abstract

IntroductionThere is a pressing need to develop novel drugs for treating patients with chronic hepatitis B (CHB), as commercially available antiviral drugs are endowed with safety and efficacy concerns.MethodsA phase III clinical trial was conducted with a therapeutic vaccine containing two antigens of the hepatitis B virus (HBV; named NASVAC) in 78 patients with CHB expressing both HBV DNA and elevated levels of alanine aminotransferase (ALT) in the blood. Five years after the end of treatment (EOT), 60 NASVAC-recipient patients were enrolled in this long-term follow-up study to evaluate the safety, antiviral potential, and liver-protective capacity of NASVAC.ResultsNASVAC exhibited an excellent safety profile 5 years after EOT. The levels of HBV DNA in the sera were reduced in 55 of the 60 patients, and 45 of them were negative for HBV DNA in the sera. ALT levels were also normalized in 40 of the 60 patients 5 years after EOT. None of the patients receiving NASVAC developed liver cirrhosis or cancer.DiscussionThe present study is the first to exhibit long-term follow-up data of a finite immune therapy for CHB that is safe and endowed with potent antiviral and liver-protecting capacities.

Published
2023
Full Text
View/download PDF

10. Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection

Author

Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Osamu Yoshida, Julio Aguilar, Guillen Nieto Gerardo, and Yoichi Hiasa

Subjects
cccDNA elimination, combination therapy, immune therapy, polyclonal immune modulator, vaccine therapy, Biology (General), QH301-705.5
Abstract

According to the World Health Organization (WHO), an estimated 296 million people are chronically infected with hepatitis B virus (HBV). Approximately 15–25% of these people develop complications such as advanced chronic liver diseases (ACLDs). Mortality due to HBV-related complications accounted for an estimated 882,000 deaths in 2019. Potent preventive vaccines have already restricted new HBV infections, and several drugs are available to treat chronic HBV infections. However, the positive impacts of these drugs have been recorded in only a few patients with chronic HBV infection. These drugs do not show long-term efficacy and cannot halt the progression to complications. Thus, more effective and evidence-based therapeutic strategies need to be urgently developed for patients with chronic HBV infection. CHB is a pathological entity induced by HBV that progresses due to impaired host immunity. This indicates the inherent limitations of antiviral-drug-based monotherapy for treating patients with chronic HBV infection. Additionally, commercially available antiviral drugs are not available to patients in developing and resource-constrained countries, posing a challenge to achieving the following WHO goal: “Elimination of Hepatitis by 2030”. As such, this review aimed to provide insights regarding evidence-based and effective management strategies for chronic HBV infection.

Published
2023
Full Text
View/download PDF

11. Sex-dependent effect of liver growth factor on atherosclerotic lesions and fatty liver disease in apolipoprotein E knockout mice

Author

Surra, J. C., Guillén, N., Barranquero, C., Jose M Arbones-Mainar, Navarro, M. A., Gascón, S., Arnal, C., Godino, J., Guzmán, M. A., Díaz-Gil, J. J., and Osada, J.

Subjects
577 - Bioquímica. Biología molecular. Biofísica, Cholesterol, lipids (amino acids, peptides, and proteins), Atherosclerosis
Abstract

Objective: Since the hepatic mitogen, liver growth factor (LGF), improves vascular structure and function in a hypertensive rat model and exhibits antioxidant activity, it may play a role in the development of atherosclerosis. Methods: To test this hypothesis, 14 male and 11 female apolipoprotein E (apoE)-deficient mice with a C57BL/6J genetic background were injected intraperitoneally twice a week with 1.7 µg of LGF per mouse for ten weeks. Plasma carbohydrates, inflammatory and lipid parameters, apolipoproteins A-I and A-II and paraoxonase activity were assessed at the end of the experimental period. Histological and chemical analyses of the livers and quantification of aortic atherosclerotic lesions were also carried out. Results: LGF administration changed neither plasma lipid nor inflammatory parameters. ApoA-I and arylesterase activity were not affected by LGF either, while apoA-II decreased significantly in males but not in females. Plasma apoA-II correlated positively with liver fat in males but negatively in females. Atherosclerotic area lesions in males receiving LGF were 25% lower than in control mice. Likewise, a significant reduction of fatty liver disease was also observed in males in association with decreased levels of insulin, leptin and resistin. Conclusion: These results indicate that administration of LGF modulates atherosclerotic lesions in a sex-dependent manner. This effect is independent of plasma cholesterol, triglycerides, IL-6, MCP-1 and TNF-α and is related to a remodelling of HDL particles characterised by a decrease in apoA-II induced by changes in hepatic mRNA expression. Hence, LGF administration could be used as a safe alternative to control fatty liver disease and atherosclerosis in males

Published
2010

12. Evaluación de la aceptación de los menús servidos en el Hospital Universitari de Sant Joan de Reus

Author

Guillén, N., Torrentó, M., Alvadalejo, R., and Salas-Salvadó, J.

Subjects
Terminal Oncological Patients, Nutrición hospitalaria, Aceptación menús, Alimentación, Home Parenteral Nutrition, Cancer
Abstract

Antecedentes y objetivos: La evaluación de la aceptación de las dietas servidas en el hospital permite introducir modificaciones que mejoren la calidad del servicio ofrecido al paciente hospitalizado, previniendo complicaciones derivadas de una nutrición incorrecta y mejorando la estancia hospitalaria. El objetivo del presente estudio fue el de analizar la aceptación de los menús ofrecidos por el servicio de restauración del hospital. Ámbito de estudio: Menús ofrecidos por el servicio de alimentación del Hospital Universitario de Sant Joan de Reus. Material y métodos: Se evaluaron un total de 160 bandejas consumidas, escogidas al azar que pertenecían a: dieta estándar, dietas especiales, incluyendo dietas túrmix. Se realizó la estimación en la cocina del hospital, a través de 2 dietistas. Se utilizó una escala visual, donde se puntuó 0: plato lleno, 1: residuo superior o igual al 75%, 2: residuo superior o igual al 50%, 3: residuo superior o igual al 25% y 4: plato vacío. Resultados: Se analizaron un total de 68 bandejas conteniendo una dieta estándar, 34 bandejas conteniendo dietas especiales y 41 bandejas con dietas túrmix. Se analizó el residuo de un total de 36 platos diferentes de la dieta estándar. La puntuación media de aceptación fue de 3,01 ± 1,30 en el caso de los primeros platos, 3,24 ± 1,11 en los segundos y 3,53 ± 0,96 en los postres. En cuanto a las dietas especiales se analizaron un total de 27 platos diferentes. La puntuación media de aceptación fue de 2,87 ± 1,38 en el caso de los primeros platos, 3,02 ± 1,27 en los segundos y 3,49 ± 1,22 en los postres. Los primeros platos de la dieta túrmix fueron los peor puntuados de entre todos los platos servidos, aunque la puntuación media general fue buena, de 2,76 ± 1,51. Conclusiones: Se ha observado en general una buena aceptación de los menús servidos en el hospital. Conocer aquellos platos que tienen una peor aceptación, permite plantear cambios en los menús hospitalarios, substituyéndolos por otros presumiblemente de mejor aceptación. Despite the fact that, in most of the series published, cancer is the most frequent base pathology for the indication of home parenteral nutrition (HPN), the use of this technique in terminally-ill patients is still a controversial issue. Our goal has been to review the evolution of cancer patients with HPN treatment from "La Paz" Hospital with a view to studying the indication, evolution and complications. We review a total of 9 terminal oncological patients who had been treated with HPN between January 2000 and December 2002. with a mean age of 60.4 (44-81) years, the most common base cancer was gastric adeno-carcinoma (44%). Intestinal obstruction in the context of peritoneal carcinomatosis was the reason for indicating HPN in 89% of cases and the median survival time was 71 (23-131) days. Catheter infection was the most frequent complication with 1.4 episodes/patient. The existence of a Home Support Team meant follow-up of patients was easier, with HPN being estimated as the treatment provided in 67% of cases. 56% of the patients were not sufficiently informed as to their underlying illness. Although HPN is one more therapeutic resource, which may or may not be used in some terminal oncological patients, we must refine the indication as much as possible to take into account a series of "systematic guarantees" including fulfilment of pertinent clinical criteria, informed consent and the adoption of a collective decision with the involvement of all the professionals monitoring the patient. We propose an action algorithm to help in improving the decision-taking process in these patients.

Published
2004

14. Evaluación de la aceptación de los menús servidos en el Hospital Universitari de Sant Joan de Reus

Author

Guillén,N., Torrentó,M., Alvadalejo,R., and Salas-Salvadó,J.

Subjects
Nutrición hospitalaria, Aceptación menús, Alimentación
Abstract

Antecedentes y objetivos: La evaluación de la aceptación de las dietas servidas en el hospital permite introducir modificaciones que mejoren la calidad del servicio ofrecido al paciente hospitalizado, previniendo complicaciones derivadas de una nutrición incorrecta y mejorando la estancia hospitalaria. El objetivo del presente estudio fue el de analizar la aceptación de los menús ofrecidos por el servicio de restauración del hospital. Ámbito de estudio: Menús ofrecidos por el servicio de alimentación del Hospital Universitario de Sant Joan de Reus. Material y métodos: Se evaluaron un total de 160 bandejas consumidas, escogidas al azar que pertenecían a: dieta estándar, dietas especiales, incluyendo dietas túrmix. Se realizó la estimación en la cocina del hospital, a través de 2 dietistas. Se utilizó una escala visual, donde se puntuó 0: plato lleno, 1: residuo superior o igual al 75%, 2: residuo superior o igual al 50%, 3: residuo superior o igual al 25% y 4: plato vacío. Resultados: Se analizaron un total de 68 bandejas conteniendo una dieta estándar, 34 bandejas conteniendo dietas especiales y 41 bandejas con dietas túrmix. Se analizó el residuo de un total de 36 platos diferentes de la dieta estándar. La puntuación media de aceptación fue de 3,01 ± 1,30 en el caso de los primeros platos, 3,24 ± 1,11 en los segundos y 3,53 ± 0,96 en los postres. En cuanto a las dietas especiales se analizaron un total de 27 platos diferentes. La puntuación media de aceptación fue de 2,87 ± 1,38 en el caso de los primeros platos, 3,02 ± 1,27 en los segundos y 3,49 ± 1,22 en los postres. Los primeros platos de la dieta túrmix fueron los peor puntuados de entre todos los platos servidos, aunque la puntuación media general fue buena, de 2,76 ± 1,51. Conclusiones: Se ha observado en general una buena aceptación de los menús servidos en el hospital. Conocer aquellos platos que tienen una peor aceptación, permite plantear cambios en los menús hospitalarios, substituyéndolos por otros presumiblemente de mejor aceptación.

Published
2004

17. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical

Author

Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Md. Helal Uddin, Md. Sakirul Islam Khan, Osamu Yoshida, Eduardo Penton, Guillen Nieto Gerardo, and Yoichi Hiasa

Subjects
chronic hepatitis b, antiviral drugs, immune therapy, therapeutic vaccine, Other systems of medicine, RZ201-999
Abstract

With the advent of various vaccines and antimicrobial agents during the 20th century, the control and containment of infectious diseases appeared to be a matter of time. However, studies unveiled the diverse natures of microbes, their lifestyle, and pathogenetic potentials. Since the ground-breaking discovery of the hepatitis B virus (HBV) by Baruch Blumberg and the subsequent development of a vaccine in the early 1980s, the main task of the scientific community has been to develop a proper management strategy for HBV-induced chronic liver diseases. In the early 1980’s, standard interferon (IFN) induced a reduction of HBV DNA levels, followed by the normalization of serum transaminases (alanine aminotransferase, ALT), in some chronic hepatitis B (CHB) patients. However, in the course of time, the limitations of standard IFN became evident, and the search for an alternative began. In the late 1980’s, nucleoside analogs entered the arena of CHB treatment as oral drugs with potent antiviral capacities. At the beginning of the 21st century, insights were developed into the scope and limitations of standard IFN, pegylated-IFN as well as nucleoside analogs for treating CHB. Considering the non-cytopathic nature of the HBV, the presence of covalently closed circular DNA (cccDNA) in the nucleus of the infected hepatocytes and HBV-induced immune-mediated liver damages, a new field of CHB management was initiated by modulating the hosts’ immune system through immune therapy. This review will discuss the nature and design of innovative immune therapy for CHB.

Published
2021
Full Text
View/download PDF

19. Structure and Content of the Entamoeba histolytica Genome

Author

Clark, C. G., Alsmark, U. C. M., Tazreiter, M., Saito, Y., Nakano, ?, Ali, V., Marion, S., Weber, C., Mukherjee, C., Bruchhaus, I., Tannich, E., Leippe, M., Sicheritz-Pontén, Thomas, Foster, P. G., Samuelson, J., Noël, C. J., Hirt, R. P., Embley, T. M., Gilchrist, C. A., Mann, B. J., Singh, U., Ackers, J. P., Bhattacharya, S., Lohia, A., Guillén, N., Duchêne, M., Nozaki, T., Hall, N., Clark, C. G., Alsmark, U. C. M., Tazreiter, M., Saito, Y., Nakano, ?, Ali, V., Marion, S., Weber, C., Mukherjee, C., Bruchhaus, I., Tannich, E., Leippe, M., Sicheritz-Pontén, Thomas, Foster, P. G., Samuelson, J., Noël, C. J., Hirt, R. P., Embley, T. M., Gilchrist, C. A., Mann, B. J., Singh, U., Ackers, J. P., Bhattacharya, S., Lohia, A., Guillén, N., Duchêne, M., Nozaki, T., and Hall, N.

Published
2007

20. Evaluación de la aceptación de los menus servidos en elHospital Universitari de sant Joan de Reus

Author

Universitat Rovira i Virgili, Guillén N; Torrentó M; Alvadalejo R; Salas-Salvadó J, Universitat Rovira i Virgili, and Guillén N; Torrentó M; Alvadalejo R; Salas-Salvadó J

Abstract

Antecedentes y objetivos: La evaluación de la aceptación de las dietas servidas en el hospital permite introducir modificaciones que mejoren la calidad del servicio ofrecido al paciente hospitalizado, previniendo complicaciones derivadas de una nutrición incorrecta y mejorando la estancia hospitalaria. El objetivo del presente estudio fue el de analizar la aceptación de los menús ofrecidos por el servicio de restauración del hospital.

Published
2004

23. Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside

Author

Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Sakirul Khan, Osamu Yoshida, Julio Cesar Aguilar, Guillen Nieto Gerardo, and Yoichi Hiasa

Subjects
chronic hepatitis B, antiviral therapy, immune modulators, innovative treatment, Medicine
Abstract

Chronic hepatitis B (CHB) is a highly complicated pathological process in which the disease is initiated by the hepatitis B virus (HBV); however, host immune responses are primarily responsible for variable extents of liver damage. If the patients with CHB remain untreated, many CHB patients will eventually develop complications like cirrhosis of the liver (LC) and hepatocellular carcinoma (HCC). In 2019, an estimated 882,000 patients died due to HBV-related complications worldwide. Accordingly, several drugs with antiviral properties have been used to treat CHB patients during the last four decades. However, the treatment outcome is not satisfactory because viral suppression is not usually related to the containment of progressive liver damage. Although proper reconstruction of host immunity is essential in CHB patients, as of today, there is no acceptable immune therapeutic protocol for them. These realities have exposed new, novel, and innovative therapeutic regimens for the management of CHB patients. This review will update the scope and limitation of the different innovative antiviral and immune therapeutic approaches for restoring effective host immunity and containing the virus in CHB patients to block progression to LC and HCC.

Published
2022
Full Text
View/download PDF

24. ACUTE TOXICITY OF TWO HERBICIDES (PROSULFOCARB AND METOLACHLOR) TO THE GIANT FRESHWATER PEARL MUSSEL ("PSEUDUNIO AURICULARIUS", SPENGLER 1793) IN THE EBRO RIVER BASIN.

Author

Nakamura, K., Elbaile, E., Guillén, N., Sosa, C., and Sorribas, V.

Subjects
ACUTE toxicity testing, FRESHWATER mussels, PESTICIDE pollution, DAPHNIA magna, POISONS
Abstract

Despite evidence that early life stages are highly sensitive to chemical contaminants, the effects of pesticides on juveniles unionid mussels are still largely unknown. Pseudunio auricularius formerly known as Margaritifera auricularia, is one of the most threatened freshwater bivalves in the world and it is classified as Critically Endangered by the IUCN. Since 2013, the population of the Ebro River basin has suffered high and unusual mortality with no known causes, and habitat pollution is one of the hypotheses raised to explain it. The aim of this study was to determine for the first time the sensitivity of captive-bred P. auricularius juveniles against two commonly used herbicides in the Ebro basin: prosulfocarb and metolachlor. Several acute toxicity tests (96 h) were conducted following an ASTM guide protocol and NaCl was used as a reference toxicant. Preliminary LC50 and LC10 results for prosulfocarb were 2.83 mg/L (0.011 mM) - 0.44 mg/L (0,002 mM) respectively, for metolachlor were 18.63 mg/L (0.066 mM) - 1.28 mg/L (0.005 mM), and for NaCl were 5.17 g/L (88.5 mM) and 0.70 g/L (12.0 mM). P. auricularius seem to be more resistant to NaCl and less to metolachlor when compared with other freshwater mussels of the Margaritiferidae family. Data on prosulfocarb toxicity on mussels are scarce but compared with Daphnia magna, P. auricularius seem to be more resistant. This study provides new data on the tolerance of P. auricularius to environmental contamination that, together with the evaluation of the chemical concentrations in the habitat, can establish more effective conservation measures to avoid new episodes of mass mortality and ultimately the extinction of this unique species. [ABSTRACT FROM AUTHOR]

Published
2022

26. A karyological study of the spirurid nematode Mastophorus muris(Nematoda: Spirocercidae)

Author

Špakulová, M., Casanova, J.C., Laplana Guillén, N., Král'ová, I., Špakulová, M., Casanova, J.C., Laplana Guillén, N., and Král'ová, I.

Abstract

The karyotype of Mastophorus muris(Gmelin, 1790) comprises four pairs of small autosomal chromosomes and two larger sex X chromosomes in females or one X chromosome in males (2n = 8 + XX/XO). All pairs of chromosomes possess rather uniform morphology without distinct primary or secondary constrictions. No heterochromatin bands were found by C-banding analysis. The absolute chromosome length ranges from 4.02 to 2.24 μm. The mean total length of the haploid complement is 14.34 μm. The course of gametogenesis represents a typical pattern common in the order Spirurida. The recently available karyotypes of spirurid nematodes have been reviewed.

Published
2000
Full Text
View/download PDF

27. The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial

Author

Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Osamu Yoshida, Sakirul Khan, Eduardo Penton, Guillen Nieto Gerardo, and Yoichi Hiasa

Subjects
chronic hepatitis B, therapeutic vaccine, HBsAg/HBcAg vaccine, NASVAC, nasal vaccine, follow-up, Medicine
Abstract

The objective of the present study was to assess the safety and efficacy of a therapeutic vaccine containing both HBsAg and HBcAg (NASVAC) in patients with chronic hepatitis B (CHB) three years after the end of treatment (EOT) as a follow-up of a phase III clinical trial. NASVAC was administered ten times by the nasal route and five times by subcutaneous injection. A total of 59 patients with CHB were enrolled. Adverse events were not seen in any of the patients. Out of the 59 CHB patients, 54 patients exhibited a reduction in HBV DNA, compared with their basal levels. Although all the patients had alanine transaminase (ALT) above the upper limit of normal (>42 IU/L) before the commencement of therapy, the levels of ALT were within the ULN level in 42 patients. No patient developed cirrhosis of the liver. The present study, showing the safety and efficacy of NASVAC 3 years after the EOT, is the first to report follow-up data of an immune therapeutic agent against CHB. NASVAC represents a unique drug against CHB that is safe, of finite duration, can be administered by the nasal route, is capable of reducing HBV DNA and normalizing ALT, and contains hepatic fibrosis.

Published
2021
Full Text
View/download PDF

28. Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial

Author

Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Osamu Yoshida, Eduardo Penton, Guillen Nieto Gerardo, and Yoichi Hiasa

Subjects
chronic hepatitis B, therapeutic vaccine, sustained effects, nasal vaccine, NASVAC, HBsAg/HBcAg vaccine, Medicine
Abstract

A phase III clinical trial in treatment-naïve patients with chronic hepatitis B (CHB) revealed the safety and considerable therapeutic efficacy of a vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NASVAC) at the end of treatment (EOT) and 24 weeks after EOT. Two years after EOT, we checked HBV DNA, alanine aminotransferase (ALT), and hepatitis B e antigen (HBeAg). The data reveal that 33 of 66 NASVAC-recipient CHB patients became negative for HBV DNA in the blood two years after EOT. The ALT levels were within the upper limit of normal (ULN) in 37 patients, although all 66 CHB patients had elevated ALT (above ULN) before the start of therapy. Out of the total twelve HBeAg-positive patients, eight patients became negative for HBeAg. None of the patients developed cirrhosis of the liver within this period. NASVAC is a finite treatment regimen with sustained antiviral and liver-protecting properties. This study is the first to report follow-up data of immune therapy for CHB. NASVAC, an immune therapy of finite duration, is endowed with sustained antiviral and liver protection properties in CHB patients.

Published
2021
Full Text
View/download PDF

35. P-TA/09- ESTUDIO PRELIMINAR DE LA SENSIBILIDAD DE Margaritifera auricularia (Spengler, 1793) A METALES.

Author

Nakamura, K., Cañete, J., Vijuesca, D., Sorribas, V., Guillén, N., Sosa, C., Sousa, R., Mesquita-Joanes, F., Armengol, X., and Ginés, E.

Abstract

Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019

36. P-TE/02- EFECTOS DEL ARSÉNICO SOBRE LA HOMEOSTASIS DEL FOSFATO EN RATAS.

Author

Lucea, S., Sosa, C., Guillén, N., and Sorribas, V.

Abstract

Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019

37. Myosin IB from Entamoeba histolytica is involved in phagocytosis of human erythrocytes.

Author

Voigt, H, Olivo, J C, Sansonetti, P, and Guillén, N

Abstract

Entamoeba histolytica is a protozoan parasite that causes amoebic dysentery in humans. The disease is prevalent worldwide. Infection with E. histolytica results in invasion of the intestine by the parasite, followed by tissue damage and inflammation. During this invasive process, parasites kill and phagocytose human epithelial cells, immune cells and erythrocytes. Expression of amoebic pathogenicity requires a dynamic cytoskeleton that allows movement, tissue penetration and changes in parasite morphology. Myosin IB is a member of the myosin I family of motor proteins. Studies conducted both with Dictyostelium discoideum, a non-pathogenic amoeba, and with the yeast Saccharomyces cerevisiae indicate the involvement of myosin IB in cellular processes including movement, phagocytosis and endocytosis. Recently, we isolated the gene encoding myosin IB from E. histolytica. Thus, we decided to analyze the role of myosin IB in pathogenesis of amoeba. Using a specific anti-myosin IB antibody, this protein was localized in cell regions including the pseudopod, vesicles and underneath the plasma membrane. When E. histolytica was activated for erythrophagocytosis, myosin IB was markedly recruited to both the phagocytic cup and around internalized phagosomes. To analyze the role of myosin IB in phagocytosis, a strain overexpressing the myosin IB gene was constructed. This strain synthesizes threefold more myosin IB than the wild-type strain. Challenge of the transfected cell line with erythrocytes showed that these amoebae were deficient in erythrophagocytosis mainly in the uptake step, suggesting a role for myosin IB in the pathogenic activity of a human parasite.

Published
1999

38. Stabilized non‐complementing diploids (Ncd) from fused protoplast products of B. subtilis.

Author

Guillén, N., Amar, M., and Hirschbein, L.

Abstract

Non‐complementing diploids (Ncd) displaying the parental phenotype can be selected from polyethylene glycol (PEG)‐treated fused polyauxotrophic protoplasts of Bacillus subtilis. These bacteria carry the two parental genomes, but only one of them is phenotypically expressed, the other being replicated but not expressed. Cellular cloning and DNA‐DNA in situ hybridization led to the discovery of non‐complementing diploid cells which at first sight could have been considered as parental haploids. The new class of stabilized Ncd (10(‐7) segregants) can be obtained either directly after the primary fusion event or from segregating Ncd after further growth. The totally inactive chromosome of a stable Ncd can be activated after PEG‐induced self fusion. DNA‐mediated transformation studies using crude stable Ncd lysates as DNA donors show low frequencies for the genetic markers from the ‘silent’ chromosome. Contrary to the unstable Ncd situation, however, these frequencies remain low even with purified donor DNA. The differences in the transformation properties of the non‐expressed markers are correlated to Ncd clone stability. These facts suggest that chromosome inactivation in PEG‐induced fusion involves at least a two‐stage process. The first would be reversible and the second irreversible, thus preserving the inactive chromosome state.

Published
1985
Full Text
View/download PDF

39. The small GTP-binding protein RacG regulates uroid formation in the protozoan parasite Entamoeba histolytica.

Author

Guillén, N, Boquet, P, and Sansonetti, P

Abstract

Entamoeba histolytica is a protozoan parasite that invades human intestine leading to ulceration and destruction of tissue. Amoebic movement and phagocytosis of human cells is accompanied by characteristic changes in cell morphology. Amoebae become polarized, developing a frontal pseudopod and a well-defined rear zone of membrane accumulation designated the uroid. In motile eukaryotic cells, a phenomenon that contributes to movement is the capping of receptors at the cell surface. During the capping process, E. histolytica concentrates ligand-receptor complexes in the uroid. Interestingly, some of these surface receptors are involved in the survival of the parasite. While looking for regulators of capping and uroid formation, we identified RacG, an E. histolytica protein that is homologous to human Rac1. This protein belongs to the Rac subfamily of small GTPases implicated in interactions between the actin cytoskeleton and the membrane of mammalian cells. Cloning of the EhracG gene and analysis of the protein activity either in murine fibroblasts or in E. histolytica revealed that EhRacG induces a characteristic Rac phenotype. When expressed in amoebae, an EhRacG-V12 mutant protein not only deregulated cell polarity, but also caused a defect in cytokinesis. Analysis of the cytoskeleton in amoebae bearing this mutant revealed that F-actin concentrated at the periphery of the cell. In addition, the number and localization of uroids were modified. These results suggest a role for EhRacG in amoebic morphogenesis and cytokinesis.

Published
1998

40. P-TE/04- ESTUDIO PRELIMINAR DEL EFECTO DE LA EXPOSICIÓN PERINATAL AL TRIBUTILESTAÑO (TBT) SOBRE EL SISTEMA DE DESTOXIFICACIÓN HEPÁTICA.

Author

Sosa, C., Guillén, N., and López, E.

Abstract

Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019

41. P-TE/03- EFECTO DE LA EXPOSICIÓN ORAL A ARSÉNICO SOBRE LAS PROTEÍNAS IMPLICADAS EN SU METABOLIZACIÓN EN RIÑÓN EN RATA.

Author

Guillén, N., Sosa, C., Lucea, S., and Sorribas, V.

Abstract

Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019

42. [Assessment of the acceptance of set meals served at the 'Sant Joan de Reus' University Hospital]

Author

Guillén N, Torrentó M, Alvadalejo R, and Jordi Salas-Salvadó

Subjects
Adult, Aged, 80 and over, Hospitalization, Food Service, Hospital, Food, Patient Satisfaction, Spain, Humans, Middle Aged, Aged
Abstract

Despite the fact that, in most of the series published, cancer is the most frequent base pathology for the indication of home parenteral nutrition (HPN), the use of this technique in terminally-ill patients is still a controversial issue. Our goal has been to review the evolution of cancer patients with HPN treatment from "La Paz" Hospital with a view to studying the indication, evolution and complications. We review a total of 9 terminal oncological patients who had been treated with HPN between January 2000 and December 2002, with a mean age of 60.4 (44-81) years, the most common base cancer was gastric adenocarcinoma (44%). Intestinal obstruction in the context of peritoneal carcinomatosis was the reason for indicating HPN in 89% of cases and the median survival time was 71 (23-131) days. Catheter infection was the most frequent complication with 1.4 episodes/patient. The existence of a Home Support Team meant follow-up of patients was easier, with HPN being estimated as the treatment provided in 67% of cases. 56% of the patients were not sufficiently informed as to their underlying illness. Although HPN is one more therapeutic resource, which may or may not be used in some terminal oncological patients, we must refine the indication as much as possible to take into account a series of "systematic guarantees" including fulfilment of pertinent clinical criteria, informed consent and the adoption of a collective decision with the involvement of all the professionals monitoring the patient. We propose an action algorithm to help in improving the decision-taking process in these patients.

43. Lessons learnt from recent citizen science initiatives to document floods in France, Argentina and New Zealand

Author

Le Coz Jérôme, Patalano Antoine, Collins Daniel, Guillén Nicolás Federico, García Carlos Marcelo, Smart Graeme M., Bind Jochen, Chiaverini Antoine, Le Boursicaud Raphaël, Dramais Guillaume, and Braud Isabelle

Subjects
Environmental sciences, GE1-350
Abstract

New communication and digital image technologies have enabled the public to produce and share large quantities of flood observations. Valuable hydraulic data such as water levels, flow rates, inundated areas, etc., can be extracted from photos and movies taken by citizens and help improve the analysis and modelling of flood hazard. We introduce recent citizen science initiatives which have been launched independently by research organisations to document floods in some catchments and urban areas of France, Argentina and New Zealand. Key drivers for success appear to be: a clear and simple procedure, suitable tools for data collecting and processing, an efficient communication plan, the support of local stakeholders, and the public awareness of natural hazards.

Published
2016
Full Text
View/download PDF

44. Preface

Author

Guillén Nieto, Victoria, Vargas Sierra, Chelo, and Williams Jellyman, Judith

Subjects
English language, PE1-3729, English literature, PR1-9680
Published
2008
Full Text
View/download PDF

48. A karyological study of the spirurid nematode Mastophorus muris (Nematoda: Spirocercidae)

Author

Špakulová M., Casanova J.C., Laplana Guillén N., and Král'ová I.

Subjects
Nematoda, Mastophorus muris, Spirurida, karyotype, chromosomes, Mus musculus, Infectious and parasitic diseases, RC109-216
Abstract

The karyotype of Mastophorus muris (Gmelin, 1790) comprises four pairs of small autosomal chromosomes and two larger sex X chromosomes in females or one X chromosome in males (2n = 8 + XX/XO). All pairs of chromosomes possess rather uniform morphology without distinct primary or secondary constrictions. No heterochromatin bands were found by C-banding analysis. The absolute chromosome length ranges from 4.02 to 2.24 μm. The mean total length of the haploid complement is 14.34 μm. The course of gametogenesis represents a typical pattern common in the order Spirurida. The recently available karyotypes of spirurid nematodes have been reviewed.

Published
2000
Full Text
View/download PDF

49. Comparación del perfil nutricional y del precio de los productos sin gluten y sus homólogos con gluten disponibles en el mercado español

Author

María Besora-Moreno, Elisenda Vilchez, Jordi Salas Salvadó, Francesc Martínez-Cerezo, Gemma Castillejo, Pablo Hernández-Alonso, Núria Guillén, Nancy Babio, Núria Lladó Bellette, Esther Roger, [Babio,N, Lladó-Bellette,N, Besora-Moreno,M, Guillén,N, Hernández-Alonso,P, Salas Salvadó,J] Universitat Rovira i Virgili. Departament de Bioquimica i Biotecnologia. Unitat Nutrició Humana. Reus, Tarragona. Spain. [Babio,N, Castillejo,G, Martínez-Cerezo,F, Salas Salvadó,J] Institut d’Investigació Sanitària Pere Virgili. [Hospital Universitari Sant Joan de Reus. Reus. Tarragona, Spain. [Babio,N, Salas Salvadó,J] Centro de Investigación Biomédica en Red, Fisiopatología de la Obesidad y Nutrición (CIBEROBN). Instituto de Salud Carlos III (ISCIII). Madrid, Spain. [Castillejo,G] Unitat de Trastorns Relacionats amb el Gluten del Camp de Tarragona. Universitat Rovira i Virgili. Reus, Tarragona. Spain. [Vilchez,E, and Roger,E] Nutrition Department. Associació Celíacs de Catalunya. Barcelona, Spain. [Hernández-Alonso,P] Department of Endocrinology and Nutrition. Hospital Universitario Virgen de la Victoria. Universidad de Málaga (IBIMA). Málaga, Spain.

Subjects
0301 basic medicine, Food intake, Glutens, Enfermedad celíaca, Dieta libre de gluten, Medicine (miscellaneous), 030209 endocrinology & metabolism, Biology, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Malabsorption Syndromes::Celiac Disease [Medical Subject Headings], Food composition database, Protein content, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 03 medical and health sciences, Diet, Gluten-Free, 0302 clinical medicine, Statistical analyses, Technology and Food and Beverages::Technology, Industry, and Agriculture::Industry::Food Industry::Food Technology::Food Quality::Nutritive Value [Medical Subject Headings], Humans, Celiac disease, chemistry.chemical_classification, Evaluación nutricional, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], 030109 nutrition & dietetics, Nutrition and Dietetics, Glutenfree diet, Enfermedad celíaca. Evaluación nutricional. Dieta libre de gluten, Commerce, Nutritional information, Nutritional assessment, Gluten, Technology and Food and Beverages::Technology, Industry, and Agriculture::Industry::Food Industry::Food Technology::Food Analysis [Medical Subject Headings], Celiac Disease, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Plant Proteins::Seed Storage Proteins::Prolamins::Glutens [Medical Subject Headings], Technology and Food and Beverages::Technology, Industry, and Agriculture::Commerce [Medical Subject Headings], chemistry, Spain, Gluten-free diet, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Nutrition Therapy::Diet Therapy::Diet, Gluten-Free [Medical Subject Headings], Gluten free, Dietary fiber, Humanities, Nutritive Value, Food Analysis
Abstract

espanolIntroduccion: hasta la fecha, una dieta sin gluten (SG) es el unico tratamiento para las personas con enfermedad celiaca. Tanto las evaluaciones de ingesta de alimentos individuales como las colectivas son un desafio debido a la falta de una base de datos de composicion de productos SG (PSG). Objetivos: describir el proceso de desarrollo de una base de datos de composicion de PSG y comparar el perfil nutricional y el precio de algunos PSG y productos con gluten. Metodos: inicialmente, se registraron un total de 216 marcas de PSG comercializadas en Espana. La informacion nutricional se recopilo de las etiquetas nutricionales y hojas informativas de los productos, que habian sido proporcionadas por las companias de alimentos o recopiladas de primera mano por los investigadores. Luego, se compararon el perfil nutricional y el precio de los grupos de cereales y subproductos alimenticios, incluidos 19 tipos de productos. Los analisis estadisticos se realizaron utilizando el programa estadistico SPSS (edicion 22.0; SPSS, Chicago, IL, EUA). Resultados: se incluyeron un total de 2247 PSG de 126 marcas de alimentos diferentes en la base de datos de composicion de PSG (CELIAC-BASE). Clasificamos estos productos en 14 grupos de alimentos. El contenido de proteinas de los PSG estudiados fue significativamente menor, y el precio de los mismos fue mas alto, que el de sus homologos con gluten. Algunos PSG, pero no todos, presentaron un mayor contenido de grasa y azucar, y un menor contenido de fibra dietetica, que sus homologos con gluten. Algunos PSG eran hasta 6 veces mas caros que sus homologos con gluten. Conclusiones: CELIAC-BASE es una herramienta pionera para dietistas-nutricionistas. Muchos PSG tienen perfiles nutricionales no saludables y deben consumirse solo ocasionalmente en una dieta equilibrada libre de gluten. EnglishBackground: to date, gluten-free (GF) diet is the only treatment available for individuals with celiac disease. Both individual and collective food intake assessments are a challenge because a food composition database of GF products (GFPs) is lacking. Objectives: to describe the process of developing a food composition database of GFPs, and to compare the nutritional profile and price of some GFPs and non-GFPs. Methods: initially, a total of 216 brands of GFPs marketed in Spain were recorded. Nutritional information was collected from nutritional labels and product fact sheets that had been provided by food companies or collected first-hand by researchers. Then, the nutritional profile and price of the cereal and cereal byproducts foodstuff groups, including 19 types of products, were compared. Statistical analyses were performed using the SPSS statistical program (22.0 edition; SPSS, Chicago, IL, USA). Results: a total of 2,247 GFPs from 126 different foodstuff brands were included in the food composition database of GFPs (CELIAC-BASE). We classified these products into 14 foodstuff groups. The protein content of the GFPs studied was significantly lower, and the price was higher, than that of their non-GFP counterparts. Some, but not all, GFPs had a higher content of fat and sugar, and a lower content of dietary fiber as compared to their non-GFP counterparts. Some GFPs were up to 6 times more expensive than the corresponding non-GFPs. Conclusions: CELIAC-BASE is a pioneering tool for dietitians. Many GFPs have poor nutritional profiles and should be consumed only occasionally in a balanced GF diet.

Published
2020

50. Three-dimensional cell culture conditions promoted the Mesenchymal-Amoeboid Transition in the Triple-Negative Breast Cancer cell line MDA-MB-231.

Author

Rodríguez-Cruz D, Boquet-Pujadas A, López-Muñoz E, Rincón-Heredia R, Paredes-Díaz R, Flores-Fortis M, Olivo-Marin JC, Guillén N, and Aguilar-Rojas A

Abstract

Introduction: Breast cancer (BC) is the leading cause of death among women, primarily due to its potential for metastasis. As BC progresses, the extracellular matrix (ECM) produces more type-I collagen, resulting in increased stiffness. This alteration influences cellular behaviors such as migration, invasion, and metastasis. Specifically, cancer cells undergo changes in gene expression that initially promote an epithelial-to-mesenchymal transition (EMT) and subsequently, a transition from a mesenchymal to an amoeboid (MAT) migration mode. In this way, cancer cells can migrate more easily through the stiffer microenvironment. Despite their importance, understanding MATs remains challenging due to the difficulty of replicating in vitro the conditions for cell migration that are observed in vivo ., Methods: To address this challenge, we developed a three-dimensional (3D) growth system that replicates the different matrix properties observed during the progression of a breast tumor. We used this model to study the migration and invasion of the Triple-Negative BC (TNBC) cell line MDA-MB-231, which is particularly subject to metastasis., Results: Our results indicate that denser collagen matrices present a reduction in porosity, collagen fiber size, and collagen fiber orientation, which are associated with the transition of cells to a rounder morphology with bleb-like protrusions. We quantified how this transition is associated with a more persistent migration, an enhanced invasion capacity, and a reduced secretion of matrix metalloproteinases., Discussion: Our findings suggest that the proposed 3D growth conditions (especially those with high collagen concentrations) mimic key features of MATs, providing a new platform to study the physiology of migratory transitions and their role in BC progression., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Rodríguez-Cruz, Boquet-Pujadas, López-Muñoz, Rincón-Heredia, Paredes-Díaz, Flores-Fortis, Olivo-Marin, Guillén and Aguilar-Rojas.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results